Journey Medical Corp (NASDAQ:DERM) — Market Cap & Net Worth
Market Cap & Net Worth: Journey Medical Corp (DERM)
Journey Medical Corp (NASDAQ:DERM) has a market capitalization of $141.46 Million ($141.46 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17855 globally and #3985 in its home market, demonstrating a 1.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Journey Medical Corp's stock price $5.19 by its total outstanding shares 27256588 (27.26 Million). Analyse Journey Medical Corp cash conversion from operations to see how efficiently the company converts income to cash.
Journey Medical Corp Market Cap History: 2021 to 2026
Journey Medical Corp's market capitalization history from 2021 to 2026. Data shows change from $146.64 Million to $141.46 Million (-12.65% CAGR).
Index Memberships
Journey Medical Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #493 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1741 of 3165 |
Weight: Journey Medical Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Journey Medical Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Journey Medical Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.90x
Journey Medical Corp's market cap is 1.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $146.64 Million | $63.13 Million | -$43.99 Million | 2.32x | N/A |
| 2022 | $52.33 Million | $73.67 Million | -$29.63 Million | 0.71x | N/A |
| 2023 | $157.00 Million | $79.18 Million | -$3.85 Million | 1.98x | N/A |
| 2024 | $106.57 Million | $56.13 Million | -$14.67 Million | 1.90x | N/A |
Competitor Companies of DERM by Market Capitalization
Companies near Journey Medical Corp in the global market cap rankings as of May 5, 2026.
Key companies related to Journey Medical Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Journey Medical Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Journey Medical Corp's market cap moved from $146.64 Million to $ 141.46 Million, with a yearly change of -12.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $141.46 Million | -32.68% |
| 2025 | $210.15 Million | +97.19% |
| 2024 | $106.57 Million | -32.12% |
| 2023 | $157.00 Million | +200.00% |
| 2022 | $52.33 Million | -64.31% |
| 2021 | $146.64 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Journey Medical Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $141.46 Million USD |
| MoneyControl | $141.46 Million USD |
| MarketWatch | $141.46 Million USD |
| marketcap.company | $141.46 Million USD |
| Reuters | $141.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Journey Medical Corp
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a top… Read more